AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7004808
Drug: Lactose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose (50 g twice a day)
Trial: 7004808
Drug: Neomycin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin (3 g/day) plus milk of magnesia
Trial: 31610249
Drug: Whole pelvis
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole pelvis radiotherapy (WPRT) 46Gy in 23 fractions + 15Gy single dose HDR BT
Trial: 31610249
Drug: Prostate-only radiotherapy
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostate-only radiotherapy (PORT) 37.5Gy in 15 fractions + 15Gy single dose HDR BT
Trial: 23801770
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg neostigmine
Trial: 23801770
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg intravenous butylscopolamine
Trial: 17513410
Drug: P125 (1.00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P125 (1.00 g protein . kg BW(‐1). d(‐1))
Trial: 17513410
Drug: P94 (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P94 (0.75 g protein . kg BW(‐1). d(‐1))
Trial: 17513410
Drug: P63 (0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P63 (0.50 g protein . kg BW(‐1). d(‐1))
Trial: 11989524
Drug: Herceptin® (adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herceptin® (adjuvant therapy)
Trial: 2757898
Drug: Aspirin (SA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (SA)
Trial: 27993911
Drug: Low-dose oxytocin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oxytocin infusion (10 U in 500 mL normal saline at 36 mL/hour for 4 hours)
Trial: 27993911
Drug: Low-dose oxytocin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oxytocin infusion plus an additional 2 U of oxytocin given over 10 min immediately after birth
Trial: 25951636
Drug: Comprehensive Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive Western medical treatment plus Compound Yindan Decoction (CYD)
Trial: 25951636
Drug: Comprehensive Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive Western medical treatment alone
Trial: 20210231
Drug: Thalidomide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (150 mg orally twice daily on days 2 through 5)
Trial: 17349809
Drug: DTaP-IPV plus
RxNorm normalized name: DTaP-IPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-IPV plus PRP approximately T at separate injection sites (group B)
Trial: 12765853
Drug: NNC‐687 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC‐687 (5 mg)
Trial: 12765853
Drug: NNC‐687 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC‐687 (10 mg)
Trial: 12765853
Drug: NNC‐687 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC‐687 (15 mg)
Trial: 8453848
Drug: Erythromycin 500
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 500 mg three times a day for 1 week
Trial: 8453848
Drug: Midazolam (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.05 mg/kg) intravenously
Trial: 30209073
Drug: Fascia Iliaca
RxNorm normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascia Iliaca Compartment Block administered by paramedics as early prehospital pain relief.
Trial: 26739688
Drug: Peginterferon lambda
RxNorm normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon lambda (180 μg weekly for 48 weeks)
Trial: 26739688
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a (weekly for 48 weeks)
Trial: 9875193
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc sulfate
Trial: 7913205
Drug: Pulsatile insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsatile insulin infusion (2.4 mU/kg/min for 2 minutes followed by 10 minutes off)
Trial: 7913205
Drug: Continuous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous insulin infusion (0.4 mU/kg/min)
Trial: 7913205
Drug: Pulsatile insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsatile insulin infusion
Trial: 30399036
Drug: Post-TB treatment
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-TB treatment MLR
Trial: 25659828
Drug: Adjunctive zonisamide
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjunctive zonisamide (target dose 8 mg/kg/day; maximum 500 mg/day)
Trial: 23571365
Drug: Enhanced daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced daily cleaning of ICU room surfaces
Trial: 21983354
Drug: Epaxal(®) 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epaxal(®) 0.25 mL
Trial: 21983354
Drug: Epaxal(®) 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epaxal(®) 0.5 mL
Trial: 19233181
Drug: Celecoxib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (both doses)
Trial: 16309928
Drug: MSM 3g
RxNorm normalized name: MSM
DrugBank: Dimethyl sulfone (DB14090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSM 3g twice a day for 12 weeks (6g/day total)
Trial: 15639691
Drug: capsule dry
RxNorm normalized name: Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule dry powder inhaler (cDPI)
Trial: 9421103
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 480 mg daily (Group-1)
Trial: 8273245
Drug: Steroid lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid lotion with additives
Trial: 8273245
Drug: Plain steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain steroid lotion
Trial: 31253613
Drug: Digital medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital medicine system (DMS) comprising an oral sensor tablet coencapsulated with an antipsychotic (aripiprazole, olanzapine, quetiapine, or risperidone), non-medicated wearable patch, mobile application, and web-based dashboard.
Trial: 28087928
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of weekly directly observed therapy
Trial: 28087928
Drug: 9 months
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 9 months of daily self-administered therapy
Trial: 24968251
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy (TRT) with 5 or 10 mg transdermal T patch daily for 12 months
Trial: 19635169
Drug: Oral heme
RxNorm normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral heme iron polypeptide (HIP; Proferrin ES) - 1 tablet twice daily
Trial: 19635169
Drug: Slow-release ferrous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release ferrous sulphate - 1 tablet twice daily (control)
Trial: 16684267
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of methanolic extract of L. pacari (n = 55)
Trial: 15087552
Drug: Intensive exercise
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive exercise therapy with immobilization of the unimpaired arm (forced use)
Trial: 15087552
Drug: Intensive exercise
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive exercise therapy without immobilization of the unimpaired arm (forced use)
Trial: 9235493
Drug: 2.4 million
RxNorm normalized name: penicillin G benzathine 2.4 million unit INTRAMUSC VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 million units of penicillin G benzathine
Trial: 9235493
Drug: Enhanced therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced therapy with 2.4 million units of penicillin G benzathine plus a 10-day course of amoxicillin and probenecid
Trial: 24731365
Drug: Soybean oligosaccharides
RxNorm normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oligosaccharides (SBOS) combined with insulin treatment
Trial: 23250527
Drug: Imudon therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imudon therapy in combination with traditional methods
Trial: 20461807
Drug: Perampanel 0.5
RxNorm normalized name: perampanel 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel 0.5 mg
Trial: 20461807
Drug: Perampanel 1
RxNorm normalized name: perampanel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel 1 mg
Trial: 14505813
Drug: 14 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 g/day fish oil (HFO)
Trial: 14505813
Drug: 7 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g/day of both safflower oil and fish oil (LFO)
Trial: 14505813
Drug: 14 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 g/day safflower oil (SO)
Trial: 8805993
Drug: Clodronate (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (1600 mg/day, orally)
Trial: 8805993
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no clodronate treatment)
Trial: 6397863
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium (1100 mg daily)
Trial: 6397863
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid (1500 mg daily)
Trial: 27329438
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of intravenous tranexamic acid (TXA)
Trial: 23564447
Drug: Myocardial contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myocardial contrast echocardiography (MCE) and low-dose dobutamine stress echocardiography (LD-DSE) in Group B (n=27)
Trial: 23564447
Drug: Myocardial contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myocardial contrast echocardiography (MCE) and low-dose dobutamine stress echocardiography (LD-DSE) in Group A (n=26)
Trial: 22440854
Drug: High polyphenol
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High polyphenol content olive oil (HPC: 366 mg/kg)
Trial: 22440854
Drug: Low polyphenol
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low polyphenol content olive oil (LPC: 2.7 mg/kg)
Trial: 17294383
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of bimatoprost 0.03%/timolol 0.5%
Trial: 17294383
Drug: Non-fixed combination
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fixed combination treatment
Trial: 12714816
Drug: PCT as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT as a prognostic indicator for valve replacement and response to medical treatment.
Trial: 12714816
Drug: PCT levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT levels to guide antimicrobial therapy before culture results.
Trial: 10588312
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg orally once daily for 5 days
Trial: 10588312
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg orally twice daily for 7 days
Trial: 8629205
Drug: Endoscopic thermal
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic thermal therapy (multipolar electrocautery or heater probe) and injection therapy
Trial: 1991216
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml 1% lignocaine
Trial: 6340813
Drug: Natural prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural prostaglandin E2 tablets
Trial: 6340813
Drug: Synthetic prostaglandin
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic prostaglandin E2 tablets
Trial: 28624695
Drug: S49076 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S49076 (600 mg qd)
Trial: 28624695
Drug: S49076 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S49076 (various doses from 15 to 900 mg)
Trial: 23963731
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (FCM) 750 mg administered in one week
Trial: 23963731
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose 200 mg administered in up to five infusions in 14 days
Trial: 15124080
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Isatis tinctoria extracts during the ICD eliciting phase
Trial: 15124080
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of tryptanthrin during the ICD eliciting phase
Trial: 15124080
Drug: Treatment after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment after the eliciting phase
Trial: 15124080
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of test substances in the UVB erythema model
Trial: 3511207
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered arginine free base 1 to 2 mmol/kg/day for 2 months (n = 13)
Trial: 3511207
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control group (n = 12)
Trial: 31386891
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg EMEND® capsules
Trial: 31386891
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg EMEND® capsules
Trial: 24401221
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (RSV10/EZE10 or RSV20/EZE10)
Trial: 10882628
Drug: Mebendazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole (200 mg twice a day for 10 days)
Trial: 10882628
Drug: Thiabendazole (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiabendazole (25 mg/kg twice a day for 10 days)
Trial: 10882628
Drug: Fluconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (400 mg initially, then 200 mg daily for 10 days)
Trial: 8936542
Drug: Succinylcholine 1
RxNorm normalized name: Succinylcholine 124 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1 mg.kg‐1
Trial: 8936542
Drug: Vecuronium 0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.16 mg.kg‐1 and Mivacurium 0.2 mg.kg‐1 (V2M2)
Trial: 8936542
Drug: Vecuronium 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.08 mg.kg‐1 and Mivacurium 0.1 mg.kg‐1 (V1M1)
Trial: 26940798
Drug: Traditional outpatient
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional outpatient physical therapy
Trial: 25608899
Drug: 30 µg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 µg/d mNGF by intramuscular injection for two courses (4 weeks for each course) with a 15-day interval
Trial: 25608899
Drug: Salvia miltiorrhiza
RxNorm normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvia miltiorrhiza Bunge and deproteinized extract of calf blood, methylcobalamin tablets, and vitamin B6
Trial: 12562651
Drug: GEM (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEM (1000 mg/m(2)) on days 1 and 8 and CBDCA (AUC 5 mg.min/ml) on day 1, 4 h before GEM (arm A)
Trial: 12562651
Drug: GEM (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEM (1000 mg/m(2)) on days 1 and 8 and CBDCA (AUC 5 mg.min/ml) on day 1, 4 h after GEM (arm B)
Trial: 2007323
Drug: Nalmefene 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 25 mg orally
Trial: 2007323
Drug: Nalmefene 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 50 mg orally
Trial: 2007323
Drug: Nalmefene 100
RxNorm normalized name: nalmefene 100 MCG in 1 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 100 mg orally
Trial: 2007323
Drug: Morphine 15
RxNorm normalized name: morphine 15 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 15 mg intramuscularly
Trial: 2007323
Drug: Morphine 30
RxNorm normalized name: ethylmorphine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 30 mg intramuscularly
Trial: 28003205
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g freeze-dried strawberry powder added to a high-fat meal (50 g total fat)
Trial: 18799887
Drug: Betadine vaginal
RxNorm normalized name: Betadine Vaginal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betadine vaginal preparation (not washed out)
Trial: 12849673
Drug: Picotamide (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picotamide (a renal TxA(2) synthase and TxA(2)/prostaglandin H(2) receptor inhibitor)
Trial: 10458353
Drug: Topical prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prostaglandin E1 gel plus 5% SEPA
Trial: 8911260
Drug: Comprehensive broad-spectrum
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive broad-spectrum empirical antimicrobial therapy (imipenem and cilastatin sodium, 500 mg, intravenously, every 6 hours)
Trial: 8911260
Drug: Limited-spectrum empirical
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limited-spectrum empirical antimicrobial therapy (cefoxitin sodium, 2 g, intravenously, every 6 hours)
Trial: 31050933
Drug: Diode Laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode Laser (DL) as an adjunct to Kirkland flap surgery
Trial: 28314755
Drug: Allopurinol dose
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol dose escalation for 12 months; increased monthly until SU <6 mg/dL.
Trial: 28314755
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group continuing current dose of allopurinol.
Trial: 28314755
Drug: Allopurinol dose
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol dose escalation group.
Trial: 15065473
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual Control group
Trial: 11320542
Drug: NSAID administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID administered 3 doses during 24 hours before surgery
Trial: 11320542
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered
Trial: 7907668
Drug: Deliberate increase
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deliberate increase of oxygen delivery index to greater than 600 mL/min per square meter using dopexamine hydrochloride infusion
Trial: 29522362
Drug: ADT+D (androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT+D (androgen deprivation therapy with docetaxel)
Trial: 29522362
Drug: ADT (androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT (androgen deprivation therapy alone)
Trial: 23491524
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg ticagrelor twice daily
Trial: 23491524
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg prasugrel once daily
Trial: 10755205
Drug: Rescue thrombolysis
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue thrombolysis with rTPA 50 mg (10 mg bolus + 40 mg in 60 minutes)
Trial: 9103739
Drug: Parent training
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent training treatment group (PT)